Asthma is a common disease-state that has a high societal cost, especially in the treatment of severe asthma. This research evaluated whether the initiation of dupilumab, a biologic indicated for asthma, reduced asthma-related emergency department visits or hospitalizations, the number of asthma rescue medications used, and the total cost of asthma-related exacerbations among MassHealth members. The data showed a reduction in emergency department visits and hospitalizations as well as the number of asthma rescue medications used; however, these findings were not statistically significant.
A Pre-Post Evaluation of Healthcare Utilization and Costs Among Patients with Asthma Initiating Dupilumab in a Medicaid Population
Commonwealth Medicine is now ForHealth Consulting at UMass Chan Medical School. More information available here. This content has not been updated with the new name.